ArticleBMC pulmonary medicine2022
Pneumonic-type invasive mucinous adenocarcinoma and infectious pneumonia: clinical and CT imaging analysis from multiple centers.
Article in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Clinicoradiologic features and evolutionary characteristics of pulmonary focal mucinous adenocarcinomas across different density patterns: a retrospective multi-center study.Quantitative imaging in medicine and surgery · 2026Article
- Invasive mucinous adenocarcinoma of the lung: integrating molecular landscape, imaging phenotypes, and translational therapeutic strategies.Translational lung cancer research · 2026Review
- Diagnosis and management of a severe ALK-positive pneumonia-type lung adenocarcinoma: a case report.Discover oncology · 2026Article
- Article
- Diagnostic utility of cryobiopsy for invasive mucinous lung adenocarcinoma.Translational lung cancer research · 2025Article
- Prognostic analysis and development of a predictive model for pulmonary invasive mucinous adenocarcinoma.Journal of thoracic disease · 2025Article
- Case Report: Do not diagnose lung cancer as pneumonia: continue to monitor a case of invasive mucinous adenocarcinoma as it progresses from small to large.Frontiers in medicine · 2025Article
- Pre-procedureDiagnostic and interventional radiology (Ankara, Turkey) · 2024Article
- Radiological Features of Primary Pulmonary Invasive Mucinous Adenocarcinoma Based on 312 Consecutive Patients.The clinical respiratory journal · 2024Article
- Mesenchymal-epithelial Transition Exon 14-skipping Mutation-positive Invasive Mucinous Adenocarcinoma of the Lung: First Case Treated with Mesenchymal-epithelial Transition-tyrosine Kinase Inhibitors.Internal medicine (Tokyo, Japan) · 2024Article
- Pneumonic-type lung adenocarcinoma with KRAS G12V mutation and sustained response to Afatinib.Pneumonia (Nathan Qld.) · 2024Article
- Comparison of the immunotherapy efficacy between invasive mucinous and non-mucinous adenocarcinoma in advanced lung cancer patients with KRAS mutation: a retrospective study.Medical oncology (Northwood, London, England) · 2023Article
- Evaluation of CT features for differentiating consolidation pattern of pulmonary MALT lymphoma from pneumonic-type lung adenocarcinoma.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPneumonic-type invasive mucinous adenocarcinoma (IMA) was often misdiagnosed as pneumonia in clinic. However, the treatment of these two diseases is different.
methodsA total of 341 patients with pneumonic-type IMA (n = 134) and infectious pneumonia (n = 207) were retrospectively enrolled from January 2017 to January 2022 at six centers. Detailed clinical and CT imaging characteristics of two groups were analyzed and the characteristics between the two groups were compared by χ
resultsA significant difference was found in age, fever, no symptoms, elevation of white blood cell count and C-reactive protein level, family history of cancer, air bronchogram, interlobular fissure bulging, satellite lesions, and CT attenuation value (all p < 0.05). Age (odds ratio [OR], 1.034; 95% confidence interval [CI] 1.008-1.061, p = 0.010), elevation of C-reactive protein level (OR, 0.439; 95% CI 0.217-0.890, p = 0.022), fever (OR, 0.104; 95% CI 0.048-0.229, p < 0.001), family history of cancer (OR, 5.123; 95% CI 1.981-13.245, p = 0.001), air space (OR, 6.587; 95% CI 3.319-13.073, p < 0.001), and CT attenuation value (OR, 0.840; 95% CI 0.796-0.886, p < 0.001) were the independent predictors of pneumonic-type IMA, with an area under the curve of 0.893 (95% CI 0.856-0.924, p < 0.001).
conclusionDetailed evaluation of clinical and CT imaging characteristics is useful for differentiating pneumonic-type IMA and infectious pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.